{"disease":{"id":"papulopustular-rosacea","name":"Papulopustular Rosacea","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:31:21.551Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":0,"pipeline_drug_count":1,"trial_count":0},"drugs":{"marketed":[],"pipeline":[{"drug_id":"pf-07038124","indication_name":"Papulopustular Rosacea","indication_type":"pipeline","phase":"Phase 2","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07038124","generic_name":"pf-07038124","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"Phosphodiesterase-4 (PDE4)","drug_class":"Phosphodiesterase-4 inhibitor","quality_score":25,"revenue":null,"mechanism":"PF-07038124 is a topical PDE4 inhibitor that blocks phosphodiesterase-4 to reduce inflammatory cytokine production in skin immune cells."}],"offLabel":[],"totalMarketed":0,"totalPipeline":1},"trials":{"data":[{"nct_id":"NCT04608500","title":"A Study (Study 2) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":771,"lead_sponsor_name":"Vyne Therapeutics Inc.","has_results":true},{"nct_id":"NCT03142451","title":"A Study (Study 1) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":751,"lead_sponsor_name":"Vyne Therapeutics Inc.","has_results":true},{"nct_id":"NCT03564145","title":"A Long-Term Safety Study of S5G4T-1 in the Treatment of Papulopustular Rosacea","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":547,"lead_sponsor_name":"Sol-Gel Technologies, Ltd.","has_results":true},{"nct_id":"NCT03276936","title":"A Study to Evaluate the Long-Term Safety of Topical Administration of FMX103 in the Treatment of Moderate to Severe Papulopustular Rosacea","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":504,"lead_sponsor_name":"Vyne Therapeutics Inc.","has_results":true},{"nct_id":"NCT03564119","title":"A Study of S5G4T-1 in the Treatment of Papularpustular Rosacea","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":372,"lead_sponsor_name":"Sol-Gel Technologies, Ltd.","has_results":true},{"nct_id":"NCT03448939","title":"A Study of S5G4T-1 in the Treatment of Papulopustular Rosacea","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":361,"lead_sponsor_name":"Sol-Gel Technologies, Ltd.","has_results":true},{"nct_id":"NCT05343455","title":"A Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea (MVOR-2)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":330,"lead_sponsor_name":"Journey Medical Corporation","has_results":true},{"nct_id":"NCT05296629","title":"A Randomized, Double-Blind Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea.","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":323,"lead_sponsor_name":"Journey Medical Corporation","has_results":true},{"nct_id":"NCT03263273","title":"Study to Evaluate the Safety and Efficacy of Topical Minocycline Gel in Patients With Papulopustular Rosacea","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":270,"lead_sponsor_name":"Hovione Scientia Limited","has_results":false},{"nct_id":"NCT05150587","title":"Safety, Efficacy and Pharmacokinetics of Rifaximin in Patients With Moderate-to-severe Papulopustular Rosacea","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":216,"lead_sponsor_name":"Alfasigma S.p.A.","has_results":true},{"nct_id":"NCT03667222","title":"Topical Minocycline Gel for Inflammatory Lesions of Papulopustular Rosacea","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":207,"lead_sponsor_name":"BioPharmX, Inc.","has_results":false},{"nct_id":"NCT05838170","title":"Study of TP-04 in Participants With Papulopustular Rosacea","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":37,"lead_sponsor_name":"Tarsus Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT06013371","title":"PDE4 Inhibition in Seborrheic Dermatitis and Papulopustular Rosacea","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":32,"lead_sponsor_name":"Icahn School of Medicine at Mount Sinai","has_results":false},{"nct_id":"NCT05675501","title":"Evaluation of Topical Encapsulated Benzoyl Peroxide on the Skin Microbiome and Skin Biophysical Properties","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":31,"lead_sponsor_name":"Sol-Gel Technologies, Ltd.","has_results":false},{"nct_id":"NCT02075671","title":"Photodynamic Therapy for Papulopustular Rosacea","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"George Washington University","has_results":true},{"nct_id":"NCT03050086","title":"Open Label Phase 2 Feasibility Study of BPX-04 Topical Minocycline Gel in Rosacea","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"BioPharmX, Inc.","has_results":false},{"nct_id":"NCT03079531","title":"Open Label Study to Assess the Effect of Secukinumab in Moderate to Severe Papulopustular Rosacea","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"Anne Chang","has_results":true},{"nct_id":"NCT06952517","title":"Efficacy and Safety of Topical Clascoterone (WINLEVI) Cream 1% in Patients With Facial Acneiform Rosacea","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"Narrows Institute for Biomedical Research","has_results":false},{"nct_id":"NCT06801717","title":"Rosacea Radiofrequency Microneedling","phase":"NA","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"University of Miami","has_results":false}],"total":19},"guidelines":[],"source":"Drug Landscape verified database"}